Disease Domain | Count |
---|---|
Neoplasms | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism PSMA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[18F] JK-PSMA-16 | Neoplasms More | Discovery |
[18F] JK-PSMA-15 | PSMA-Positive Tumor More | Discovery |
[18F] JK-PSMA-18 | Neoplasms More | Discovery |
Cocoa flavanols | Essential Hypertension More | Pending |
Anti-CD3-anti-CD19 bispecific monoclonal antibody(University of Cologne) ( CD19 x CD3 ) | Lymphoid Leukemia More | Pending |